Advertisement


Charles D. Blanke, MD, on Oregon’s Death With Dignity Act

2016 Palliative Care in Oncology Symposium

Advertisement

Charles D. Blanke, MD, of the Oregon Health & Science University and Southwest Oncology Group, discusses the nearly 20 years’ experience with Oregon’s Death With Dignity (DWD) Act, a voter initiative that led to the first such law enacted in the United States (Abstract 44).



Related Videos

Palliative Care
Issues in Oncology

Sriram Yennu, MD, on Patient Perception of Curability

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a study of an international cohort of patients with advanced cancer who received palliative care. Nearly half the patients incorrectly believed their cancer was curable (Abstract 5).

Palliative Care
Symptom Management

Joseph A. Greer, PhD, on An App for Adherence to Oral Chemotherapy

Joseph A. Greer, PhD, of Massachusetts General Hospital, discusses the development of a mobile application to address treatment adherence and symptoms (Abstract 104).

Global Cancer Care
Issues in Oncology
Palliative Care

Emily Haozous, PhD, RN, on Cultural Differences in End-of-Life Care

Emily Haozous, PhD, RN, of the University of New Mexico, discusses health disparities and cultural differences in palliative and end-of-life care, with case study examples drawn from American Indian communities.

Palliative Care
Issues in Oncology

J. Nicholas Dionne-Odom, PhD, on Supporting Family Caregivers: The ENABLE Model

J. Nicholas Dionne-Odom, PhD, of the University of Alabama at Birmingham, discusses the “hidden” health-care workforce of family caregivers and what clinicians can do to help ease the burden on families.

Palliative Care
Supportive Care
Hematologic Malignancies

Areej El-Jawahri, MD, on Hematologic Malignancies: Integrating Palliative Care in Treatment

Areej El-Jawahri, MD, of Massachusetts General Hospital, discusses ways in which palliative care can reduce symptoms, improve quality of life, reduce depression and anxiety, and potentially optimize end-of-life care for patients with hematologic malignancies.

Advertisement

Advertisement




Advertisement